Más literatura científica

Por favor tenga en cuenta que la mayoría de los resúmenes sólo están disponibles en inglés. Por favor utilice el botón “volver” de su explorador para retornar a esta página.

Datos clínicos 2002

• PET studies of 18F-memantine in healthy volunteers

  Ametamey SM, Bruehlmeier M, Kneifel S, Kokic M, Honer M, Arigoni M, Buck A, Burger C, Samnick S, Quack G, Schubiger PA (2002). Nucl Med Biol, 29 (2): 227-31.

• Alzheimer’s Disease – Neuroprotection

  Danysz W, Möbius HJ (2002). In: Lodge D et al. (eds). Ionotropic Glutamate Receptors as Therapeutic Targets. F.P. Graham Publishing Co., Johnson City, TN, 612-636.

• The agony and (rational) alternative. Recommendations of the drug commission on antidementia agents

  Dietmaier O (2002). Pharm Unserer Zeit, 31 (4): 394-400.

• Symptomatic therapy of Alzheimer dementia

  Förstl H (2002). Wien Med Wochenschr, 152 (3-4): 77-80.

• Starting Alzheimer therapy in early stages whenever possible. Activities of daily living remain intact longer

  Fuchsberger T, Padberg F, Faltraco F, Möller HJ, Hampel H (2002). MMW Fortschr Med, 144 (20): 36-9.

• New therapies. New Alzheimer’s treatments that may ease the mind

  Helmuth L (2002). Science, 297, 1260-2.

• Dementing disorders. What benefits do the new anti-dementia drugs have

  Ihl R (2002). MMW Fortschr Med, Suppl 2: 24-6, 28-9.

• New approaches to clinical trials in vascular dementia: memantine in small vessel disease

  Möbius HJ, Stöffler A (2002). Cerebrovasc Dis, 13 (Suppl 2): 61-6.

• Eficacia y seguridad de memantina en los pacientes con demencia vascular de intensidad leve a moderada: ensayo aleatorizado y controlado con placebo (MMM 300)

  Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F (2002). Stroke, 33 (7): 1834-9.

• Dementia

  Parsons CG, Stöffler A, Winblad B (2002). In: Lodge D et al. (eds). Ionotropic Glutamate Receptors as Therapeutic Targets. F.P. Graham Publishing Co., Johnson City, TN, 229-262.

• Long-term treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderately severe to severe Alzheimer’s disease

  Reisberg B, Ferris SH, Möbius HJ, Stöffler A, Schmitt F, Doody RS (2002). Neurobiology of Aging, 23 (1S): S555.

• Measuring cognition in advanced Alzheimer’s disease for clinical trials

  Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Möbius HJ, Stöffler A (2002). J Neural Transm Suppl, (62): 135-48.

• Use of memantine in progressive glaucoma. Case report

  Schroder A, Erb C (2002). Klin Monatsbl Augenheilkd, 219 (7): 533-6.

• Estudio multicéntrico, a doble ciego y controlado con placebo de memantina en la demencia vascular de intensidad leve a moderada (MMM 500)

  Wilcock G, Möbius HJ, Stöffler A (2002). Int Clin Psychopharmacol, 17 (6): 297-305.

• Effect of long-term treatment with memantine

  Wimo A, Winblad B, Stoffler A, Wirth Y, Möbius HJ (2002). 8th Int Conf Alzheimers Dis Rel Disord abstr, 167.

• Glutamate receptors as a target for Alzheimer’s disease – are clinical results supporting the hope?

  Winblad B, Möbius HJ, Stöffler A (2002). J Neural Transm Suppl, (62): 217-25.

Datos preclínicos 2002

• Treatment of mild cognitive impairment: value of citicoline

  Abad Santos F, Novalbos J, Gallego Sandin S, Garcia AG (2002). Rev Neurol, 35 (7): 675-82.

• Restorative effects of glutamate antagonists in experimental parkinsonism

  Archer T, Palomo T, Fredriksson A (2002). Amino Acids, 23 (1-3): 71-85.

• Ketamine, an N-methyl-D-aspartate receptor antagonist, inhibits the spinal neuronal responses to distension of the rat urinary bladder

  Castroman PJ, Ness TJ (2002). Anesthesiology, 96 (6): 1410-9.

• Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits

  Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y, Cui J, Tu S, Sevarino KA, Nakanishi N, Tong G, Lipton SA, Zhang D (2002). Nature, 415 (6873): 793-8.

• Memantine and the processing of the β-amyloid precursor protein. 32nd Society for Neuroscience Meeting, Nov. 2-7, 2002, Orlando, New Orleans, USA

  Chen D, Alley GM, Ge1 YW, Farlow MR, Banerjee PK, Lahiri DK (2002). Neurosci. Abst., 28.

• Neuroprotective potential of ionotropic glutamate receptor antagonists

  Danysz W, Parsons CG (2002). Neurotox Res, 4 (2): 119-26.

• Non-cholinergic strategies for treating and preventing Alzheimer’s disease

  Doraiswamy PM (2002). CNS Drugs, 16 (12): 811-24.

• NMDA receptor antagonists to characterize rat renal organic cation transporter function

  Fourie J, Escobar MR, Sitar DS (2002). Eur J Pharmacol, 452 (1): 1-10.

• Functional alteration by NMDA antagonist: Effects of L-Dopa, neuroleptics drug and postnatal administration

  Fredriksson A, Archer T (2002). Amino Acids, 23 (1-3): 111-32.

• Effects of the NMDA antagonist memantine on human methamphetamine discrimination

  Hart CL, Haney M, Foltin RW, Fischman MW (2002). Psychopharmacology (Berl), 164 (4): 376-84.

• Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore

  Kashiwagi K, Masuko T, Nguyen CD, Kuno T, Tanaka I, Igarashi K, Williams K (2002). Mol Pharmacol, 61 (3): 533-45.

• Continuous brachial plexus analgesia and NMDA-receptor blockade in early phantom limb pain: A report of two cases

  Kiefer RT, Wiech K, Topfner S, Haerle M, Schaller HE, Unertl K, Birbaumer N (2002). Pain Medicine, 3: 156-160.

• Memantine. Merz.

  Kilpatrick GJ, Tilbrook GS (2002). Curr Opin Investig Drugs, 3 (5): 798-806.

• Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia

  Kim TW, Kim DM, Park KH, Kim H (2002). Korean J Ophthalmol, 16 (1): 1-7.

• Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry

  Leis HJ, Fauler G, Windischhofer W (2002). J Mass Spectrom, 37(5): 477-80.

• A review of chemical agents in the pharmacotherapy of addiction

  Levi MS, Borne RF (2002). Curr Med Chem, 9 (20): 1807-18.

• Comparison of the anticonvulsant activity of organic mono- and di-cations and their potential to inhibit NMDA and AMPA glutamate receptors

  Lukomskaia NIa, Rukoiatkina NI, Gorbunova LV, Gmiro VE, Bol’shakov KV, Magazanik LG (2002). Ross Fiziol Zh Im I M Sechenova, 88 (9): 1161-71.

• Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1-40)

  Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G (2002). Brain Res, 958 (1): 210-21.

• Phenytoin blocks retinal ganglion cell death after partial optic nerve crush

  Naskar R, Quinto K, Romann I, Schuettauf F, Zurakowski D (2002). Exp Eye Res, 74 (6): 747-52.

• Different action of memantine and caroverine on glutamatergic transmission in the mammalian cochlea

  Oestreicher E, Ehrenberger K, Felix D (2002). Adv Otorhinolaryngol, 59: 18-25.

• Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine

  Paul C, Bolton C (2002). J Pharmacol Exp Ther, 302 (1): 50-7.

• Trends in neuroprotection

  Pop E (2002). Arch Soc Esp Oftalmol, 77 (6), 295-7.

• Electrophoretic behavior of adamantane derivatives possessing antiviral activity and their determination by capillary zone electrophoresis with indirect detection

  Reichova N, Pazourek J, Polaskova P, Havel J (2002). Electrophoresis, 23 (2): 259-62.

• Memantine does not block antiaggressive effects of morphine in mice

  Rodriguez-Arias M, Maldonado C, Aguilar MA, Minarro J (2002). Behav Pharmacol, 13 (3): 249-52.

• Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats

  Rogoz Z, Skuza G, Maj J, Danysz W (2002). Neuropharmacology, 42(8): 1024-30.

• Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials

  Sang CN, Booher S, Gilron I, Parada S, Max MB (2002). Anesthesiology, 96 (5): 1053-61.

• Modulation of formalin-induced behaviors and edema by local and systemic administration of dextromethorphan, memantine and ketamine

  Sawynok J, Reid A (2002). Eur J Pharmacol, 450 (2): 153-62.

• Depolarization-induced superoxide radical formation in rat hippocampal slices

  Saybasili H, Yuksel M, Haklar G, Yalcin AS (2002). Neurochem Res, 27 (6): 473-6.

• Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model

  Schuettauf F, Quinto K, Naskar R, Zurakowski D (2002). Vision Res, 42 (20): 2333-7.

• NMDA receptor antagonists prevent the development of acute tolerance to the effects of morphine in the rat formalin test

  Sewostjanowa N, Bespalov A, Danysz W (2002). Soc. Neurosci. Abst, 28, in press.

• Chronic multichannel recordings from organotypic hippocampal slice cultures: protection from excitotoxic effects of NMDA by non-competitive NMDA antagonists

  Shimono K, Baudry M, Panchenko V, Taketani M (2002). J Neurosci Methods, 120 (2): 193-202.

• Molecular rearrangements of the extracellular vestibule in NMDAR channels during gating

  Sobolevsky AI, Beck C, Wollmuth LP (2002). Neuron, 33 (1): 75-85.

• Neuroprotective effect of memantine in different retinal injury models in rats

  WoldeMussie E, Yoles E, Schwartz M, Ruiz G, Wheeler LA (2002). J Glaucoma, 11 (6): 474-80.